Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075024 | 0.92 | S1PR1 (0.68) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL2916510 | 0.92 | S1PR1 (0.59) | S1PR1S1PR3MAP4K4MINK1 | |
| Hydrochloric Acid SCHEMBL3092240 | 0.92 | S1PR1 (0.68) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL3076059 | 0.88 | S1PR1 (0.62) | S1PR1S1PR3MAP4K4MINK1 | |
| Hydrochloric Acid SCHEMBL3070835 | 0.87 | S1PR1 (0.61) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL2915924 | 0.80 | S1PR1 (0.54) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL1969510 | 0.78 | S1PR1 (0.69) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL3070539 | 0.76 | S1PR1 (0.58) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL13045463 | 0.75 | S1PR1 (0.75) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL2991967 | 0.74 | S1PR1 (1.00) | S1PR1S1PR3MAP4K4MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2220077-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009080730-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080730-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SSB, RORC, OXA1L | S1PR1 605/4885S1PR3 505/4885MAP4K4 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.